<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.9.1" -->
<rss version="0.92">
<channel>
	<title>BullseyeMicrocaps.com</title>
	<link>http://www.bullseyemicrocaps.com</link>
	<description>Stock Picks that hit the Bullseye</description>
	<lastBuildDate>Mon, 06 Sep 2010 13:10:19 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>Gold Up 1%; Silver Up 4% Last Week &#8211; Maintain Upward Momentum and Challenge Resistance</title>
		<description><![CDATA[Mark O&#8217;Byrne submits:
Gold
Last week&#8217;s early September relief rally continued this morning as   equities have risen again in Asia and Europe. Gold is one of the   strongest currencies in the world this morning, along with the yen.   While the dollar is flat, sterling has fallen sharply against all   [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3393</link>
			</item>
	<item>
		<title>Crossing the Biotech &#8216;Valley of Death&#8217;: From Innovation to Cure</title>
		<description><![CDATA[Jason Chew submits: 
The term &#8220;Valley of Death&#8221; has come to describe the period of transition when a developing technology is deemed promising, but too new to validate its commercial potential and thereby attract the capital necessary for its continued development1. During this transition, there is often a funding gap due to the weariness of [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3392</link>
			</item>
	<item>
		<title>Gold and Silver Market Suppression Failures Flash Buy Signal, Part 5</title>
		<description><![CDATA[Robert Kientz submits:


Gold and silver, like other commodities, have an intrinsic value, which is not arbitrary, but is dependent on their scarcity, the quantity of labour bestowed in procuring them, and the value of the capital employed in the mines which produce them.



Complete Story &#187;
]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3391</link>
			</item>
	<item>
		<title>Arena&#8217;s Lorcaserin: Weighed Down by Qnexa and Meridia</title>
		<description><![CDATA[Joseph Krueger submits: 
Before the FDA review panel&#8217;s of Vivus&#8217;s (VVUS) drug Qnexa, I expressed significant doubt that the panel review would be positive based primarily on the safety issues surrounding one of its ingredients topiramate here.  The safety issues had to do with contraindications between topiramate itself as well as contraindications with the [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3390</link>
			</item>
	<item>
		<title>Fifty Years of Suppressing Silver</title>
		<description><![CDATA[Jeff Nielson submits:
Sophisticated precious metals investors are well-aware of the rampant manipulation  of the gold and silver markets. They are also generally aware of the  reason for such manipulation. A rapid rise in the price of gold and  silver is like an economic &#8220;warning siren&#8221; &#8211; alerting savers that their  wealth [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3389</link>
			</item>
	<item>
		<title>Mining Juniors Take the Gold Bull Lead</title>
		<description><![CDATA[Marco G. submits:

The Gold price has been on a tear this summer since July 26th, 2010. Gold has moved from $1155 USD to a peak of $1255 USD reached on September 1st, 2010.  That is a move in the price of Gold of about $100 or 9%.  As the author types on September [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3388</link>
			</item>
	<item>
		<title>Gold Resource Corp: The Power of Dividends</title>
		<description><![CDATA[I&#8217;ve been an investor in Gold Resource Corporation (GORO) since October 2006.  I advised them for just under two years, bought shares in the open market, and have since watched their dream become a reality.  The stock itself is arguably the best performing gold stock during the 2006-2010 timeframe.  The GORO story [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3387</link>
			</item>
	<item>
		<title>A &#8216;Stealth Rally&#8217; in Solar Stocks</title>
		<description><![CDATA[Dr. Duru submits: 
OK, by &#8220;stealth&#8221; I really mean I have not paid close enough attention  to the rallies in several solar stocks. 2010 has been a year of true  divergence for solar stocks. Some solar stocks have been in year-to-date  rallies and others have been declining all year. The net result [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3386</link>
			</item>
	<item>
		<title>Genzyme, Sanofi May Eventually Come to Terms: Focus on Biotech Deals</title>
		<description><![CDATA[The Burrill Report submits: 
By Marie Daghlian
Sanofi-Aventis (SNY) made a formal offer to acquire Genzyme (GENZ) for $69 per share, an offer that was unanimously rejected by Genzyme&#8217;s board of directors as unrealistic and opportunistic. 
Complete Story &#187;
]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3384</link>
			</item>
	<item>
		<title>Another Big Bet on Obesity: Takeda Puts Orexigen on Solid Ground</title>
		<description><![CDATA[The Burrill Report submits: 
By Michael Fitzhugh
Japan&#8217;s Takeda (TKPHF.PK) is placing summer&#8217;s second major bet on an obesity drug with a $50 million investment in Orexigen&#8217;s (OREX) Contrave, a combination drug meant to help people tackle the biology and behaviors behind overeating. Payments of more than $1 billion await Orexigen if it hits unspecified regulatory [...]]]></description>
		<link>http://www.bullseyemicrocaps.com/?p=3383</link>
			</item>
</channel>
</rss>
